Pharming Group N.V. today announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida on November 6-10.

Pharming Group today announced the implementation of an organizational restructuring to accelerate the Company’s growth.

Pharming Group N.V. today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025.

Pharming Group N.V. announces that Pharming management will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025.

Pharming Group N.V. today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025.

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of August:

Pharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2025.

Pharming Group N.V. confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2025 and provide a business update on Thursday, July 31, 2025.

For media and investors only